Neoadjuvant Treatment of Fruquintinib Combined With Concurrent Chemoradiotherapy for LARC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2022

Primary Completion Date

May 31, 2024

Study Completion Date

November 30, 2025

Conditions
Rectal Cancer
Interventions
DRUG

fruquintinib + concurrent radiotherapy + chemotherapy

"mFOLFOX6: The mFOLFOX6 regimen will be administered on Day 1 of each treatment cycle. This regimen consists of oxaliplatin 85 mg/m2 IV given over 2 hours, leucovorin 400 mg/m2 IV given over 2 hours, and fluorouracil 400 mg/m2 IV bolus, followed by fluorouracil 1200 mg/m2 per day for 2 days, continuous infusion.~fruquintinib: 3mg/d, qd po, for 7 weeks continuously.~Radiation Therapy: radiation 45.0\~50.0 Gy (1.8-2.0 Gy/day or 25 fractions weeks 3-7)"

All Listed Sponsors
lead

Henan Provincial People's Hospital

OTHER

NCT05575635 - Neoadjuvant Treatment of Fruquintinib Combined With Concurrent Chemoradiotherapy for LARC | Biotech Hunter | Biotech Hunter